Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 26 clinical trials
Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma

metastatic NPC without prior chemotherapy for relapse. Secondary: - To evaluate the efficacy profile of oxaliplatin (XELOX) in patients with metastatic NPC in terms of

metastatic nasopharyngeal carcinoma
xelox
capecitabine
metastasis
nasopharyngeal carcinoma
  • 15 views
  • 07 Nov, 2020
  • 1 location
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Placebo Combined With Gemcitabine Plus Cisplatin as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer.

  • 7 views
  • 25 Jan, 2021
  • 41 locations
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their

  • 292 views
  • 26 Jan, 2021
  • 135 locations
Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma

The investigators do the clinical trial (patients with metastatic nasopharyngeal carcinoma treated with donafenib after failure of standard therapy) to assess safety and efficacy of donafenib in

metastatic nasopharyngeal carcinoma
gemcitabine
prothrombin
fluoropyrimidine
nasopharyngeal carcinoma
  • 0 views
  • 25 Jan, 2021
  • 1 location
SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

This is an open label, phase Ib Study of SHR-1701 in patients with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).

metastatic nasopharyngeal carcinoma
administration intravenous
iv infusion
nasopharyngeal carcinoma
renal function
  • 8 views
  • 27 Jan, 2021
  • 1 location
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

This is an open-label, single center, phase I trial to evaluate the safety and efficacy of toripalimab and gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma.

metastatic nasopharyngeal carcinoma
gemcitabine
systemic chemotherapy
nasopharyngeal carcinoma
measurable disease
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma

This is a single-arm, non-randomised study including patients with EBER positive nasopharyngeal carcinoma with recurrent or metastatic disease not amenable to curative treatment, who have received at least 1 regimen of platinum containing chemotherapy.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Cisplatin Plus Docetaxel Versus Cetuximab Cisplatin and Docetaxel in Metastatic Nasopharyngeal Carcinoma

chemoradiation in previously untreated patients metastatic nasopharyngeal carcinoma (mNPC) to determine whether the addition of cetuximab to induction chemotherapy and chemoradiation could improve therapeutic

metastatic nasopharyngeal carcinoma
cancer
concurrent chemoradiation
prothrombin
cetuximab
  • 84 views
  • 21 Jan, 2021
  • 8 locations
Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma

nasopharyngeal carcinoma.

metastatic nasopharyngeal carcinoma
administration intravenous
iv infusion
chemotherapy regimen
creatinine clearance rate
  • 5 views
  • 24 Jan, 2021
EBV-TCR-T YT-E001 for Patients With EBV-positive Recurrent or Metastatic NPC

TCR-T cell therapy experienced a breakthrough for treating tumors in recent years. Phase I / II trial of NY-ESO-1-specific TCR-T treatment for synovial sarcoma and melanoma conducted by the Rosenberg team at the National Cancer Institute showed that 61% Synovial cell sarcoma and 55% melanoma had therapeutic responses. These and …

cancer
potassium
epstein-barr virus dna
anticoagulants
metastasis
  • 0 views
  • 24 Jan, 2021
  • 1 location